The recall includes devices distributed between Oct. 13, 2017, and June 9, 2023.
The implantable defibrillators detect and treat irregular heartbeats by producing an electric shock, but if that shock underperforms or does not happen, the malfunction “can lead to cardiac arrest, other serious injury or death,” according to the FDA.
As of July 18, there have been 28 complaints, 22 injuries and zero deaths reported.
Medtronic told providers in May to not prophylactically replace devices and reprogram the high voltage therapy pathways.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
